`Case 1:24-cv-00053-TSK Document 18-5 Filed 06/26/24 Page 1 of 4 PagelD #: 2742
`
`EXHIBIT 5
`EXHIBIT 5
`
`
`
`Case 1:24-cv-00053-TSK Document 18-5 Filed 06/26/24 Page 2 of 4 PageID #: 2743
`
`Kayali, Kathryn
`From:
`Sent:
`To:
`Cc:
`Subject:
`
`
`
`Robert Oakes <RMO@FR.com>
`Thursday, April 4, 2024 9:08 PM
`Argall, Arthur; Louis Fogel; Shaun Van Horn; Rae Crisler; Autumn Wu; SERVICE - Formycon Team
`Eylea; Eylea.Biosimilars@weil.com; REGENERONPATENT@lists.kellogghansen.com; Janette Riebe
`RE: Regeneron v. Formycon, C.A. 23-97 - Service of Formycon AG's Redacted Documents (March 21,
`2024 Filing)
`
`Arthur,
`
`
`The version of Dr. Boyle’s Formycon declara(cid:415)on that Regeneron a(cid:425)empted to introduce at Dr. Boyle’s deposi(cid:415)on in the
`Samsung Bioepis case today is marked Confiden(cid:415)al on its face. As your email acknowledges, Regeneron asked for
`redacted versions of Formycon’s expert declara(cid:415)ons that it could share with your client. The redacted version of Dr.
`Boyle’s declara(cid:415)on we provided on May 27 redacts the OCEO informa(cid:415)on, and can be shared with your client. At no
`point did Regeneron ask to use Formycon’s expert declara(cid:415)ons in other cases, and Regeneron had no legi(cid:415)mate reason
`to a(cid:425)empt to use Dr. Boyle’s Formycon declara(cid:415)on in the Samsung Bioepis case. This is par(cid:415)cularly true because
`Regeneron will depose Dr. Boyle in the Formycon case tomorrow, and will be able to ques(cid:415)on Dr. Boyle on the opinions
`he provided in the Formycon case at that deposi(cid:415)on. If Regeneron wanted to challenge the designa(cid:415)on of Dr. Boyle’s
`redacted declara(cid:415)on as Confiden(cid:415)al, it should have followed the procedure to do that. D99, ¶21. Regeneron chose
`instead to spring the use of the redacted declara(cid:415)on in a deposi(cid:415)on Formycon’s counsel was not even a part of, and
`shouldn’t be surprised that we objected to that tac(cid:415)c.
`
`
`Per your request of this a(cid:332)ernoon, Formycon will provide a further redacted version of Dr. Boyle’s declara(cid:415)on that
`redacts Confiden(cid:415)al and OCEO informa(cid:415)on. You have had the May 27 redacted version for over a week, given your late
`request for an addi(cid:415)onal version and the commitments of our team, I can’t commit to providing that by tomorrow.
`Regardless, there is absolutely no prejudice to Regeneron’s ability to depose Dr. Boyle on these issues tomorrow.
`Regeneron is free to introduce Dr. Boyle’s unredacted Formycon declara(cid:415)on at tomorrow’s deposi(cid:415)on. If Regeneron
`wants its in‐house counsel to be present, Regeneron can ques(cid:415)on Dr. Boyle on the May 27 redacted version of his
`declara(cid:415)on which redacts OCEO informa(cid:415)on.
`
`
`Regards,
`
`
`Bob
`
`
`Robert M. Oakes :: Principal :: Fish & Richardson P.C.
`222 Delaware Avenue 17th Floor, P.O. Box 1114, Wilmington, DE 19899
`302 778 8477 direct :: oakes@fr.com
`
`
`
`
`From: Argall, Arthur <aargall@wc.com>
`Sent: Thursday, April 04, 2024 2:05 PM
`To: Robert Oakes <RMO@FR.com>; Louis Fogel <fogel@fr.com>; Shaun Van Horn <vanhorn@fr.com>; Rae Crisler
`<crisler@fr.com>; Autumn Wu <qwu@fr.com>; SERVICE ‐ Formycon Team <SERVICE‐Formycon_Team@fr.com>
`Cc: Eylea@wc.com; Eylea.Biosimilars@weil.com; REGENERONPATENT@lists.kellogghansen.com; Janette Riebe
`
`1
`
`
`
`Case 1:24-cv-00053-TSK Document 18-5 Filed 06/26/24 Page 3 of 4 PageID #: 2744
`
`<riebe@fr.com>
`Subject: RE: Regeneron v. Formycon, C.A. 23‐97 ‐ Service of Formycon AG's Redacted Documents (March 21, 2024 Filing)
`
`
`[This email originated outside of F&R.]
`
`
`
`Counsel,
`
`
`On Monday, March 25, Regeneron requested that Formycon “provide a version of the declara(cid:415)ons and briefs filed on
`March 21, 2024 by Formycon with Formycon’s OCEO informa(cid:415)on removed, and a separate version with Formycon’s
`confiden(cid:415)al informa(cid:415)on removed, that we are able to share with our client by this Wednesday, March 27.” Email from
`R. Krawetz (Mar. 25, 2024, 4:55 PM). On Wednesday, March 27, Formycon then provided a redacted version of Dr.
`Boyle’s declara(cid:415)on and stated below that Dr. Boyle’s declara(cid:415)on “did not include confiden(cid:415)al informa(cid:415)on that was
`not also OCEO informa(cid:415)on, thus there is only one redacted copy” of it. During the deposi(cid:415)on today of Dr.
`Boyle in the Regeneron v. Samsung Bioepis case, counsel for Formycon (present in the office at the (cid:415)me)
`reversed posi(cid:415)on and now appears to maintain that there is addi(cid:415)onal confiden(cid:415)al informa(cid:415)on in Dr. Boyle’s
`declara(cid:415)on that is not OCEO informa(cid:415)on. Please immediately provide a redacted version of Dr. Boyle’s
`Formycon declara(cid:415)on with all confiden(cid:415)al and OCEO informa(cid:415)on redacted by 6 PM this evening so that
`Regeneron may use it at tomorrow’s deposi(cid:415)on.
`
`
`Formycon’s reversal is highly prejudicial to Regeneron’s ability to prepare for and conduct its deposi(cid:415)on of Dr. Boyle,
`and Regeneron reserves all rights to further relief from the Court.
`
`
`Best,
`
`
`Arthur J. Argall
`Associate | Williams & Connolly LLP
`680 Maine Avenue, S.W., Washington, DC 20024
`(P) 202‐434‐5251 | (202) 434‐5029
`aargall@wc.com | www.wc.com
`
`
`From: Janette Riebe <riebe@fr.com>
`Sent: Wednesday, March 27, 2024 5:24 PM
`To: Service ‐ Regeneron Opposing Counsel <Service‐Regeneron_Opposing_Counsel@fr.com>
`Cc: SERVICE ‐ Formycon Team <SERVICE‐Formycon_Team@fr.com>
`Subject: Regeneron v. Formycon, C.A. 23‐97 ‐ Service of Formycon AG's Redacted Documents (March 21, 2024 Filing)
`
`
`
`
`Counsel:
`
`
`Below please find a link for accessing the following materials, all of which were filed under seal on March 21,
`2024, with Formycon’s OCEO informa(cid:415)on redacted. These files did not include confiden(cid:415)al informa(cid:415)on that
`was not also OCEO informa(cid:415)on, thus there is only one redacted copy of each document. A password for the
`zipped file will be forwarded via a separate email. Let me know if you have any difficul(cid:415)es accessing the
`documents.
`
`
` REDACTED Defendant Formycon AG’s Response in Opposi(cid:415)on to Regeneron’s Mo(cid:415)on for Preliminary
`Injunc(cid:415)on (Dkt. 155‐3);
`
`2
`
`
`
`Case 1:24-cv-00053-TSK Document 18-5 Filed 06/26/24 Page 4 of 4 PageID #: 2745
`
` REDACTED Declara(cid:415)on of Laird Forrest, Ph.D., with REDACTED Exhibits 14‐16 (Dkt. 156–156‐2);
` REDACTED Declara(cid:415)on of Arun Sharma (Dkt. 158);
` REDACTED Declara(cid:415)on of Denis M. Boyle, Ph.D., with REDACTED Exhibits 4, 7‐9 (Dkt. 159‐1); and
` REDACTED Declara(cid:415)on of Niall Barron, Ph.D., with REDACTED Exhibits 6‐7, 9‐11 (Dkt. 159‐6–159‐8).
`
`
`
`The following filed documents did not contain Formycon OCEO nor Confiden(cid:415)al informa(cid:415)on, and thus are not
`provided at the link below:
`
`
` Mo(cid:415)on to Par(cid:415)ally Strike the Opening Declara(cid:415)on of Dr. Ranjit Singh Atwal (Dkt. 154);
` Memorandum in Support of Their Mo(cid:415)on to Par(cid:415)ally Strike the Opening Declara(cid:415)on of Dr. Ranjit Singh
`Atwal (Dkt. 154‐2), with Exhibit 1 (Dkt. 154‐3);
` Declara(cid:415)on of Peter M. Tessier, Ph.D., with Exhibits 1‐56 (Dkt. 157‐1); and
` Responsive Declara(cid:415)on of Dr. Holly Pren(cid:415)ce, Ph.D., with Exhibits 1‐61 (Dkt. 160, 161, 162).
`
`
`
`h(cid:425)ps://send.fr.com/link/pvAZ1jA7gnQXzBbl7DM3Cl
`
`
`Best regards,
`
`
`Janette D. Riebe
`Litigation Paralegal ■ Fish & Richardson P.C.
`
`T: 612 337 2513
`riebe@fr.com | fr.com
`60 South 6th Street, Suite 3200, Minneapolis, MN 55402
`
`
`
`
`
`
`***************************************************************************************************
`*************************
`This email message is for the sole use of the intended recipient(s) and may contain confidential
`and privileged information. Any unauthorized use or disclosure is prohibited. If you are not the
`intended recipient, please contact the sender by reply email and destroy all copies of the original
`message.
`***************************************************************************************************
`*************************
`
`
`
`This message and any attachments are intended only for the addressee and may contain information that is privileged and
`confidential. If you have received this message in error, please do not read, use, copy, distribute, or disclose the contents of the
`message and any attachments. Instead, please delete the message and any attachments and notify the sender immediately. Thank
`you.
`
`
`***************************************************************************************************
`*************************
`This email message is for the sole use of the intended recipient(s) and may contain confidential
`and privileged information. Any unauthorized use or disclosure is prohibited. If you are not the
`intended recipient, please contact the sender by reply email and destroy all copies of the original
`message.
`***************************************************************************************************
`*************************
`
`3
`
`